Subtitle
Post-treatment neuroendocrine outcomes among pediatric brain tumor patients: Is there a difference between proton and photon therapy?
Subtitle
Post-treatment neuroendocrine outcomes among pediatric brain tumor patients: Is there a difference between proton and photon therapy?
Proto therapy Time
February 2022
Executive summary
This study compared the neuroendocrine outcomes of 112 pediatric primary brain tumor patients treated with XRT(n = 80) or PRT (n = 32). With a median follow-up of 6.3 years for XRT and 4.4 years for PRT, the common endocrinopathies occurred were growth hormone deficiency (26% XRT, 38% PRT) and hypothyroidism (29% XRT, 19% PRT). In CSI cohort, PRT patients had less hypothyroidism (p = 0.045). Sex hormone deficiency developed in 17.1% of the XRT CSI group but did not occur in the PRT CSI group.
Key content topics
Top cancer treatments
Related contents
Webinar
18 October 2024
Empowering Cancer Care with Proton Therapy
Rakesh
Jalali
Srinivas
Chilukuri
Daniela
Alterio
Proton Therapy Publication
April 2024
Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer.
Proton Therapy Publication
April 2024
The Use of Proton and Carbon Ion Radiation Therapy for Sarcomas.
Proton Therapy Publication
March 2024
How proton therapy fits into the management of adult intracranial tumors.
Proton Therapy Publication
September 2023
Ultra-High Dose-Rate Proton FLASH Improves Tumor Control.
Proton Therapy Publication
June 2023
Gastrointestinal bleeding/ulcer among paediatric cancer patients after proton beam therapy.
Webinar
February 6, 2023
Reirradiation
Jing
Zeng
Proton Therapy Publication
June 2022
Dose-escalated proton therapy with elective nodal irradiation and concomitant chemotherapy for unresectable, borderline resectable, or medically inoperable pancreatic cancer: a phase II trial.
Proton Therapy Publication
June 2022
Proton Therapy in the Management of Pancreatic Cancer.